Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2021 16:01 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)

eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021Fast Track designation granted by the U.S....
September 29, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820Denali to host analyst and investor...
September 27, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
September 09, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
August 26, 2021 11:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
August 04, 2021 16:01 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
July 25, 2021 11:05 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)

Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in...
July 15, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
June 28, 2021 08:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
May 03, 2021 08:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...